Amgen Sues Coherus Over Chemo Drug Trade Secrets

By John Kennedy (March 7, 2017, 8:36 PM EST) -- Amgen Inc. on Friday sued Coherus Biosciences Inc., which is seeking approval of a biosimilar of Amgen's chemotherapy drug Neulasta, telling a California court that Coherus has been poaching its employees and using stolen trade secrets to speed up its biosimilar production process.

The drugmaker accused disloyal former employees now working for Coherus of running a "massive conspiracy" that gave the biosimilar company an unfair head start in bringing its Neulasta biosimilar to market. Coherus said in a Monday statement that it rejects Amgen's claims and that the suit is nothing more than an effort to delay Coherus from entering the...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!